Search Results | Showing 41 - 50 of 93 results for "Sciences" |
| | | ... to virology and oncology. Royalty Pharma, which is in the business of acquiring pharmaceutical royalties in the life sciences industry, will provide information on medical conditions, clinical trials, therapies and technologies that may lead to breakthrough ... |
| | | | ... contrary, new research suggests money does in fact buy happiness. A study conducted by Proceedings of the National Academy of Sciences (PNAS) in the US found that while personal wellbeing does not increase above incomes of $75,000, emotional experience ... |
| | | | ... this could help keep them safe," HESTA chief investment officer Sonya Sawtell-Rickson said. "Our investments in life sciences are supporting jobs and growth in the sector where HESTA members work, while making a positive contribution to their financial ... |
| | | | ... Neiron said. Holdings in the new fund include healthcare leaders such as Lilly, Bristol-Myers Squibb, Resmed and Gilead Sciences, he said. Meanwhile, GOAT is a high conviction international equity portfolio of at least 50 attractively priced wide moat ... |
| | | | ... Zoom, protective healthcare equipment producer 3M, global payments giant Mastercard and pharmaceutical company Gilead Sciences. WealthO2 co-founder and managing director Shannon Bernasconi said the new low cost and innovative Chi-X solution would enable ... |
| | | | ... recommended solutions," he said. "These include data centers... However, we are also looking further into areas such as life sciences, bio-medical and industrial cold storage." Despite the heavy sell off in REITs in March and several macro forces still ... |
| | | | ... provider 3M, payments giant Mastercard, supermarket conglomerate Walmart and anti-viral pharmaceutical company Gilead Sciences. Following today's announcement, there are now 35 US listed companies available to Australian investors via Chi-X's TraCRs. ... |
| | | | ... long-term financial success. In a virtual conference held by Morningstar, the investment manager's global head of decision sciences Ryan Murphy said arming investors with the skills to limit behavioural biases can be especially helpful during a crisis. ... |
| | | | ... flopped in human trials saw markets fall overnight. Originally reported by the Financial Times, the publisher said Gilead Sciences antiviral drug remdesivir did not reduce the coronavirus pathogen in bloodstreams, nor did it improve patients' conditions ... |
| | | | ... for specialised roles in the industry, the report said. Full-time workers in mathematics, statistics and information sciences were rewarded with a 44% salary increase over the period, earning $118,937 per annum on average. Teaching aides and special ... |
|